ClinicalTrials.gg
RecruitingNCT06212193Updated Nov 4, 2026

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

An interventional study of Trillium™ in Tricuspid Regurgitation and Tricuspid Regurgitation Functional, sponsored by Innoventric LTD. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Innoventric LTD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
32nd of 42
25 · median 63
Started
2024
with 7 others
No phase
39 of 60
18 open now
Primary completion
2026-12
later than 12 of 35 live
Registered
42nd of 60
by date

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 32nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2024, is one of 39 with no phase, reaches primary completion later than 12 of the 35 other live ones, and was the 42nd registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).

Read the detailed description

Prospective, single arm, multi-center, Early Feasibility Study (EFS) to assess the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).

Up to fifteen (15) patients at up to 10 US investigational sites and 3 German investigational sites will be enrolled. All enrolled study patients will be assessed at baseline, during the procedure, at discharge, and after 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years following the index procedure.

03

Conditions studied

  • Tricuspid Regurgitation
  • Tricuspid Regurgitation Functional

Keywords

  • Tricuspid valve
  • Transcatheter
  • Tricuspid Regurgitation
  • Tricuspid valve insufficiency
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has TR graded as severe or greater
  • Peak central venous pressure of ≥ 15mmHg
  • Patient has functional classification of III or IV
  • Patient is not eligible for standard-of-care surgical or interventional therapy or has refused standard-of-care surgical and interventional therapy or has received standard-of-care TR therapy and remains symptomatic

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from participation if ANY of the following criteria apply:

  • Severe RV dysfunction defined by TAPSE, RVEF, or RVFAC.
  • Anatomical suitability according to CT scan.
  • Systolic Pulmonary Artery Pressure > 65mmHg
  • Moderate or more mitral valve stenosis
  • Greater than moderate mitral valve regurgitation or aortic valve stenosis/regurgitation
  • Moderate mitral valve regurgitation combined with moderate aortic valve stenosis/regurgitation
  • Kidney dysfunction with estimated (eGFR) \< 35 ml/min/1.73 m2 within 60 days prior to the index procedure or patient is on chronic dialysis
  • Liver cirrhosis or moderate or severe liver disease (Child-Turcotte-Pugh class B or C, or a score of 7 or higher)
  • Thrombocytopenia ( count\< 80,000/mm3) or thrombocytosis (Platelet count > 750,000/mm3) within 14 days of the index procedure
  • In the opinion of the Investigator or the study eligibility committee, the patient's \< 12 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Innoventric Trillium™ Stent Graft

    Transcatheter cross-caval tricuspid valve replacement with the Innoventric Trillium™ Stent Graft

    Device: Trillium™

Interventions

  • DeviceTrillium™

    Trillium™ Stent Graft for Heterotopic Cross-Caval Tricuspid Valve Replacement

06

What researchers measure

Primary outcomes

  1. Rate of Major Adverse Events [Safety endpoint]

    Rate of device or procedure-related Major Adverse Events (MAEs) And Rate of unplanned surgery or re-intervention due to a life-threatening device or procedure failure

    Time frame: at the end of the procedure, at discharge - typically within a week, and 30 days

  2. Technical Performance

    Successful access, delivery, and retrieval of the Trillium™ delivery system, device is anchored both in SVC and IVC \[at the end of the procedure\] And No need for re-intervention due to device valve regurgitation or para-stent leak \[at discharge, and 30 days\]

    Time frame: at the end of the procedure, at discharge - typically within a week, and 30 days

Secondary outcomes

  1. Rate of Major Adverse Events [Safety endpoint]

    * Composite of all device or procedure-related MAEs \[at 3 months, 6 months, 1, 2, 3, 4, and 5 years\]. * Device thrombosis, evaluated by Echocardiography \[at 30 days, 6 months, 1, 2, and 4 years\]. * Device Migration as evaluated by Echocardiography or CMR \[at 6 months\]

    Time frame: at 3 months, 6 months, 1, 2, 3, 4, and 5 years

  2. Efficacy endpoint

    One or more of the following- * TR grade as measured on the device valves by Echocardiography, or reduction in peak CVP as measured by right heart catheterization \[at the end of the procedure\] * TR grade as measured on the device valves by Echocardiography \[at 30 days, 6-month, 1-year, 2-year, and 4-year\] * Rate of hospitalizations for HF \[at 6-month, and 1-year\] * HF functional class (NYHA) \[at 30 days, 3-month, 6-month,1-year, 2-year, 3-year, 4-year, and 5-year\] * Six-minute walk test (6MWT) \[at 30 days, 6-month, 1-year, 2-year, and 4-year\] * The Kansas City Cardiomyopathy Questionnaire (KCCQ) \[at 30 days, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year, and 5-year\] * Patient Global Assessment (PGA) for Tricuspid Regurgitation Valve Treatment \[at 30 days, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year, and 5-year\]

    Time frame: at 30 days, 3-month, 6-month, 1-year, 2-year, 3-year, 4-year, and 5-year

Other outcomes

  1. Observational endpoint

    All-cause mortality

    Time frame: at 30 days, 3 months, 6 months, 1, 2, 3, 4, and 5 years

07

Study locations

10 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 28 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Aug 2025 → Dec 2026 and completion Aug 2030 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 18, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Dec 20, 2026was Aug 2025
CompletionEst.
Dec 2031was Aug 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed
Show 2 removed
  • Lankenau Heart Institute · Philadelphia, United States
  • German Heart Center at Charité (DHZC) · Berlin, Germany
Nov 4, 2026
Primary completion
Aug 2025→Dec 20, 2026
Nov 4, 2026
Study completion
Aug 2030→Dec 2031
Nov 4, 2026
Enrollment
15→25
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites removed
    Show 2 removed
    • Lankenau Heart Institute · Philadelphia, United States
    • German Heart Center at Charité (DHZC) · Berlin, Germany
    Primary completion Aug 2025→Dec 20, 2026
    Study completion Aug 2030→Dec 2031
    Enrollment 15→25
    + 4 other changes: index terms, verification date, oversight details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06212193
Lead sponsor
Innoventric LTD
Collaborators
Innoventric Inc.
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Aug 5, 2024
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Chen Lereya
Contact
chen@innoventric.com
+972-52-8981783
Amir Danino
Contact
amir@innoventric.com
+972-54-7256930

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion